2016-06-01 19:21:38 UTC

Sofosbuvir Plus Ribavirin Shows Promise in Complicated HCV Genotype 2 Patients

June 1, 2016

Phase 4 study results published in CGH find that this treatment combo is effective in almost 80 percent of HCV genotype 2 patients with cirrhosis.

A new Clinical Gastroenterology and Hepatology (CGH) article in press highlights the results of a Phase 4, open-label study to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus (HCV) genotype 2 infection and compensated cirrhosis.

The research team, led by Samuel B. Ho, MD, conclude that 12-weeks treatment with sofosbuvir and ribavirin led to a sustained virologic response (SVR) in almost 80 percent of veterans with HCV genotype 2 infection, compensated cirrhosis and multiple comorbidities, regardless of their treatment history.

The presence of depression, post-traumatic stress disorder or substance use did not impact the treatment outcome in this study, indicating that patients with these coexisting conditions can expect to achieve SVR rates similar to those without them.

This study represents the largest group of HCV genotype 2 patients with cirrhosis studied in a prospective trial of sofosbuvir and ribavirin to date. Review the full study on the CGH website (login required).

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Oct. 11, 2017

Statin use is probably associated with lower risk of hepatic decompensation and mortality, and might reduce portal hypertension, in patients with CLDs.

Cirrhosis Presenting as Cutaneous Calciphylaxis

Oct. 11, 2017

A 73-year-old woman with a history of hypertension presented with a 3-month history of a painful, non-healing right calf ulcer and 2–3 weeks of painful, dusky purple patches on the right thigh.